This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2002 Dec;168(6):2451-3.

doi: 10.1016/S0022-5347(05)64165-1.

Editorial: States and state transitions are all that really matter

Howard I Scher, William K Kelly

PMID: 12441937
DOI: 10.1016/S0022-5347(05)64165-1

Editorial

Editorial: States and state transitions are all that really matter

Howard I Scher et al. J Urol. 2002 Dec.

. 2002 Dec;168(6):2451-3.

doi: 10.1016/S0022-5347(05)64165-1.

Authors

Howard I Scher, William K Kelly

PMID: 12441937
DOI: 10.1016/S0022-5347(05)64165-1

No abstract available

PubMed Disclaimer

Comment on

Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.
Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Berry W, et al. J Urol. 2002 Dec;168(6):2439-43. doi: 10.1016/S0022-5347(05)64163-8. J Urol. 2002. PMID: 12441935 Clinical Trial.
Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer.
Urakami S, Igawa M, Kikuno N, Yoshino T, Kishi H, Shigeno K, Shiina H. Urakami S, et al. J Urol. 2002 Dec;168(6):2444-50. doi: 10.1016/S0022-5347(05)64164-X. J Urol. 2002. PMID: 12441936 Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon